Antipsychotics and Metabolic Syndrome
Suspended
- Conditions
- Metabolic Syndrome
- Registration Number
- NCT00636753
- Lead Sponsor
- Glostrup University Hospital, Copenhagen
- Brief Summary
The purpose of the study is to determine whether antipsychotic treatment is influence psychiatric patients due to endocrine and metabolic status and quality of life.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- SUSPENDED
- Sex
- Male
- Target Recruitment
- 60
Inclusion Criteria
- Gender male
- Age 18-45
- Debut drug-naive schizophrenics,
- Caucasians
- Consent given to take part in the project
Exclusion Criteria
- Compliance-problems
- Major lung-/kidney/hart/lever disorders
- Abuse of alcohol/drugs
- Diabetes 1 and 2
- Antihypertensive
- Anticholesterol-reducing medication
- Patients under duress
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link antipsychotics to metabolic syndrome in psychiatric patients?
How do antipsychotic drugs compare to standard-of-care treatments in managing metabolic syndrome symptoms?
Are there specific biomarkers that predict antipsychotic-induced metabolic syndrome risk in patients?
What adverse events are associated with antipsychotic treatment in patients with metabolic syndrome?
What combination therapies or alternative drugs are being explored for antipsychotic-induced metabolic syndrome?
Trial Locations
- Locations (1)
Psychiatric Center Glostrup
🇩🇰Nordre Ringvej 28-69, Glostrup, Denmark
Psychiatric Center Glostrup🇩🇰Nordre Ringvej 28-69, Glostrup, Denmark